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Available online 21 June 2018Background: Recent developments in cellular reprogramming technology enable the production of virtually
unlimited numbers of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM). Although
hiPSC-CM share various characteristic hallmarks with endogenous cardiomyocytes, it remains a question as to
what extent metabolic characteristics are equivalent to mature mammalian cardiomyocytes. Here we set out
to functionally characterize the metabolic status of hiPSC-CM in vitro by employing a radionuclide tracer uptake
assay.
Material and methods: Cardiac differentiation of hiPSC was induced using a combination of well-orchestrated ex-
trinsic stimuli such as WNT activation (by CHIR99021) and BMP signalling followed byWNT inhibition and lac-
tate based cardiomyocyte enrichment. For characterization of metabolic substrates, dual tracer uptake studies
were performed with 18F 2 fluoro 2 deoxy D glucose (18F-FDG) and 125I β methyl iodophenyl pentadecanoic
acid (125I-BMIPP) as transport markers of glucose and fatty acids, respectively.
Results: After cardiac differentiation of hiPSCs, in vitro tracer uptake assays confirmed metabolic substrate shift
from glucose to fatty acids that was comparable to those observed in native isolated human cardiomyocytes. Im-
munostaining further confirmed expression of fatty acid transport and binding proteins on hiPSC-CM.
Conclusions:During in vitro cardiacmaturation, we observed ametabolic shift to fatty acids, which are known as a
main energy source of mammalian hearts, suggesting hi-PSC-CM as a potential functional phenotype to investi-
gate alteration of cardiacmetabolism in cardiac diseases. Results also highlight theuse of available clinical nuclear
medicine tracers as functional assays in stem cell research for improved generation of autologous differentiated
cells for numerous biomedical applications.edicine/
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Human induced pluripotent stem cells (hiPSC) have been shown to
represent a virtually unlimited source of spontaneously contracting
cardiomyocytes by applying appropriate differentiation protocols [1].Comprehensive Heart
er Strasse 6, 97080
an open access article underThese pluripotent stem cell technologies promise improved therapies
of cardiovascular diseases such as patient-specific cardiac repair with-
out immune rejection [2], more robust disease modelling, scalable and
standardized drug discovery screenings, as well as stratified or person-
alized toxicology studies. A bottleneck of induced cardiomyocyte tech-
nology is the difficulty in establishing standardized differentiation
strategies for homogeneous and fully maturated cardiomyocytes [3, 4].
The cardiac differentiation process is known to be very delicate and
needs to be tightly orchestrated by the sequential activation of different
signallingpathways resulting in variable cellularmaturitywith different
protocols [5, 6]. Recent protocol improvements achieved by BMP andthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tain pure andmatured cardiomyocyte populations [7]. However, the de-
velopment of appropriate functional assays to functionally characterize
these differentiated cells remains a challenge.
Molecular imaging using radionuclide tracers is a clinically routinely
available technology for the visualization of keymolecular events in car-
diovascular disease [8–10]. Radiolabelled energy substrate analogues
such as 125I β methyl iodophenyl pentadecanoic acid (125I-BMIPP)
(fatty acid transport marker) [8] and 18F 2 fluoro 2 deoxy D glucose
(18F-FDG) (glucose transport marker) [9] are well-established for the
clinical diagnosis of ischemic heart diseases. We hypothesized that
these well-characterized radionuclide tracers in molecular imaging
can be used to assess the functional characteristics of hiPSC-derived
cardiomyocytes (hiPSC-CM) and as such provide a novel tool for func-
tional validation of hiPSC-CM in vitro. In this study, we harnessed the ra-
dionuclide technology in order to test to what extent hiPSC-CM are
metabolically equivalent to mature mammalian cardiomyocytes.
2. Material and methods
2.1. Radiopharmaceuticals
18F-FDG was supplied from the in-house University Hospital of Würzburg cyclotron
unit. 125I-BMIPPwas kindly gifted fromNihonMedi-Physics Co., Ltd., Japan. Radiochemical
purity was N95% for both radiolabeled compounds.
2.2. Reprogramming to hiPSC (AF-, K-, and FS-hiPSC)
hiPSC from human adult skin fibroblasts (AF-hiPSC) were obtained by transgene-free
technology as previously described [11], after obtaining informed consent and ethical
clearance by the ethics committee of the University ofWürzburg, Germany (ethical report
number 96/11). Briefly, human fibroblasts obtained from a skin punch biopsy were in-
fected with the human STEMCCA Cre-Excisable constitutive polycistronic (OKSM)
lentiviral vector and were seeded on irradiated mouse embryonic fibroblasts in a
reprogramming medium. After 3 weeks, iPSC-like colonies were picked, expanded on
hESC-qualifiedMatrigel™ (Corning, USA) - coated dishes in mTeSR™1 media (STEMCELL
Technologies, Germany) and characterized for the pluripotencymarkers Oct4 and SSEA-4.
Additionally, hiPSCs obtained from human keratinocytes (K-hiPSC, kindly gifted by
Dr. Stefan Liebau, University of Tübingen, Germany, [12]) and foreskin fibroblasts derivedFig. 1. Schematic presentation of the cell preparhiPSC (FS-hiPSC) generated from normal human dermal fibroblasts (NHDF; PromoCell,
Germany) were used in this study.
2.3. Cardiac differentiation of hiPSCs
hiPSC (AF-, K- and FS-hiPSC, each cell line fromone donor)were differentiated as pre-
viously described with minor changes [13]. Respectively, 10 times of cardiac differentia-
tions with AF-hiPSC and 3 times of cardiac differentiations with both K- and FS-hiPSC
were performed. For each cardiac differentiation, we carried out n = 3–9 technical
measurement replicates (in total, n = 12–30). Briefly, hiPSC were maintained on hESC-
qualified Matrigel™-coated plates in mTeSR™ 1 medium until they reached 80%
confluency (37 °C, 5% CO2). Cardiac differentiation was induced by BMP4 (25 ng/ml)
(Thermo Fisher Scientific, USA) and CHIR99021 (5 μM) (Axon Medchem, The
Netherlands) in RPMI1640 medium (Thermo Fisher Scientific) containing B27
(Thermo Fisher Scientific), β-Mercaptoethanol (100 μM) (Thermo Fisher Scientific)
and L-Ascorbic acid (50 μg/ml) (Sigma-Aldrich Inc., USA) as basal medium A. After 24 h,
the medium was replaced with the same basal medium A containing CHIR99021 (5 μM)
for another 24 h. Afterwards, cells were kept in basal medium B, media similar to media
A but containing B27 without insulin (Thermo Fisher Scientific), for 24 h, then the me-
dium was replaced with basal medium B containing the WNT inhibitor IWR1 (10 μM)
(Sigma-Aldrich Inc.) for 5 to 7 days followed by further cultivation in basal medium
A. Subsequently, cells were kept in basal medium A for 4 to 5 days followed by replace-
ment with cardiac enrichment medium (RPMI1640 without glucose (Thermo Fisher
Scientific) + 4 mM sodium L-lactate (Sigma-Aldrich Inc.)). Cells were kept in cardiac en-
richment medium for 4 to 5 days. After this enrichment phase, the mediumwas switched
back to basal medium A. Native adult human cardiomyocytes (Adult hCM) were isolated
from left atrial appendage biopsy specimens belonging to patientswhich underwent heart
surgery as described [14, 15] with minor modifications after obtaining informed consent
and ethical approval by the local ethics committee from the University Hospital
Würzburg, Germany (ethical report number 182/10) and kindly gifted from Department
Tissue Engineering and Regenerative Medicine, University of Würzburg, Germany.
2.4. Dual-tracer uptake assay for the assessment of functional energy
substrates transport
Glucose and fatty acids uptake were assessed with 18F-FDG and 125I-BMIPP as previ-
ously reported [8, 9] with a minor modification. In brief, cells (1.0–2.0 × 106 cells/well in
12-well plate) were washed with Dulbecco's phosphate-buffered saline (DPBS, Sigma-
Aldrich Inc.). DPBS containing 3.0–5.0 × 10−1 MBq/mL 18F-FDG and 4.0 × 10−2 MBq/mL
125I-BMIPP was added to each well. After 30 min incubation (37 °C, 5% CO2), the medium
was removed and 18F-FDG as well as 125I-BMIPP uptake into the cells were immediately
terminated by applying 1 ml of ice-cold DPBS. The cells were washed once with 1 ml ofation and radionuclide tracer uptake assay.
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sate was measured by a γ-counter (FH 412; Frieseke & Höpfner, Germany) (Fig. 1). A
tracer uptake ratio of 125I-BMIPP radioactivity divided by 18F-FDG radioactivity was
calculated.2.5. Immunostaining
Immunostaining was performed using antibodies for octamer binding transcription
factor 4 (Oct4) (1:100; sc-5279, Santacruz Biotechnology, USA), cardiac Troponin TFig. 2. Results of FACS analysis for pluripotency marker SSEA-4 and cardiomyocyte marker
cardiomyocyte markers (cTnT, α-actinin) as well as gap junctional marker (Cx43) (B). Scale
stem cells. AF-hiPSC-CM: AF-hiPSC derived cardiomyocytes, Adult hCM: isolated native adult h(cTnT) (1:100; ab-8295, Abcam), α-actinin (1:400; A7811, Sigma-Aldrich Inc.),
Connexin 43 (Cx43) (1:1000; ab-11370, Abcam), long-chain fatty acid transport pro-
tein 6 (SLC27A6) (1:50; 600-401-EP0, Rockland Immunochemicals Inc., USA), cardiac
fatty acid binding protein (FABP3) (1:50; TA590642-OR, BioCat GmbH, Germany) and
cluster of differentiation 36 (CD36) (1:100; ab-17044, Abcam) as primary antibodies.
Briefly, cells were fixed and incubated with the primary antibody at 4 °C overnight
followed by incubation with the secondary antibodies at room temperature for 1 h.
After nuclear staining with DAPI (1 μg/ml; 10236276001, Sigma-Aldrich Inc.), micro-
graphs were taken with an Oxion3070 microscope (Euromex Microscopen BV,
Netherlands).SIRPα (A). Representative immunostaining images for pluripotency marker (Oct4) and
bars:100 μm, AF-hiPSC: human adult skin fibroblast-derived human induced pluripotent
uman cardiomyocytes.
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To detect cell surface expression of signal regulatory protein α (SIRPα) and stage-
specific embryonic antigen-4 (SSEA-4), 1 × 106 trypsinized cells were incubated with
SIRPα antibodies (1:11; 130-099-783, Miltenyi Biotec Inc.) or SSEA-4 antibodies (1:11;
130-098-34, Miltenyi Biotec Inc.) for 15 min at 4 °C, respectively, and measured for
fluorescence-activated cell sorting (FACS) analysis. The analysis was performed using
FlowJo software (FlowJo LLC).2.7. Statistics
Results are given as mean ± SD. The two-tailed paired Student's t-test was used
to compare differences between two dependent groups and the two-tailed indepen-
dent Student's t-test between independent groups. Multiple group comparisons were
performed using analysis of variance (ANOVA). A value of p b 0.05 was considered
statistically significant. Statistical analysis was done with StatMate III (ATMS Co.,
Ltd.).Fig. 3.Results of dual-tracer uptake studieswith 18F 2 fluoro 2 deoxy D glucose (18F-FDG) and 12
and fatty acid transport, respectively. A metabolic substrate shift from glucose to fatty acids
replicates) (A). A metabolic substrate shift during cardiac differentiation was confirmed in thr
fatty acid transport protein (SLC27A6) and fatty acid binding protein (FABP3) is confirmed by
100 μm, K-hiPSC: human keratinocytes-derived induced pluripotent stem cells, FS-hiPSC: hu
derived cardiomyocytes, FS-hiPSC-CM: FS-hiPSC derived cardiomyocytes, 2nd Ab only: only th3. Results
hiPSC were successfully differentiated into cardiomyocytes using a
well-established protocol [13] in all three tested hiPSC lines. Cardiac dif-
ferentiation after maturation and enrichment process was confirmed
by the disappearance of Oct4 positivity and appearance of α-actinin,
cTnT and Cx43 positive cells as assessed by immunofluorescence staining.
FACS analysis further confirmed the differentiation with an increased
number of SIRPα positive cells (N90%) and a decreased number of
SSEA-4 positive cells (b10%) after cardiac differentiation (week 8) (Fig. 2).
Dual-tracer uptake analysis with 18F-FDG and 125I-BMIPP was per-
formed at different stages of cardiac differentiation of hiPSC. Tracer up-
take ratios of 125I-BMIPP/18F-FDG began to increase at week 2 after
cardiac specification and proliferationwithWNT inhibitor IWR1, further
increased with cardiac enrichment process using lactate, and plateaued5I-β-methyl-iodophenyl-pentadecanoic acid (125I-BMIPP) as a functionalmarker of glucose
is observed during cardiac differentiation of hiPSC (n = 3–9 per uptake measurement
ee different hiPSC lines (n = 3–9 per uptake measurement replicates) (B). Expression of
immunostaining in hiPSC-derived cardiomyocytes as well as Adult hCM. (C). Scale bars:
man foreskin fibroblasts-derived induced pluripotent stem cells, K-hiPSC-CM: K-hiPSC
e secondary antibodies are used as a negative control.
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BMIPP/18F-FDG uptake was observed in three different hiPSC lines
after cardiac differentiation and was also found in isolated native
Adult hCM (Fig. 3B). The results of the in vitro tracer uptake study indi-
cated a shift of metabolic substrate usage from glucose to fatty acids
after cardiac differentiation. Immunofluorescence staining of hiPSC-
CM and Adult hCM confirmed strong positivity for fatty acid transporter
(SLC27A6) and fatty acid binding protein (FABP3) while hiPSC showed
no expression of bothmarkers (Fig. 3C, Supplemental Figs. 1 and 2). Ad-
ditionally, increased expression of cluster of differentiation 36 (CD36)
during cardiac differentiation of hiPSC was also confirmed by immuno-
staining (Supplemental Fig. 3).
4. Discussion
The present study is the first to describe functional properties of
an energy substrate shift of hiPSC after cardiac differentiation. We
elaborated a tracer uptake assay for the assessment of energy sub-
strate transport activity of hiPSC and differentiated cardiomyocytes.
Decreased 18F-FDG (radiolabelled glucose analog) uptake along with
increased 125I-BMIPP (radiolabelled fatty acid analog) uptake con-
firmed an energy substrate shift from glucose to fatty acids consis-
tent with cardiac differentiation. The metabolic shift is one of the
unique characteristics of in vivo mammalian cardiomyocytes that
primarily use of fatty acids (N70%) as an energy source (Fig. 4). Im-
munofluorescence staining confirmed the cellular expression of
fatty acid transport and binding proteins on hiPSC-CM supporting
the results of tracer uptake assays.
Cardiac differentiation of hiPSC is increasingly recognized in cardio-
vascular research as a platform for drug discovery, toxicology studies,
disease modelling and comprehension of a development of the heart
[16]. Many different protocols for cardiac differentiation from pluripo-
tent stem cells have been reported [12]. In this study, we employed a
novel, robust strategy to obtain cardiomyocytes from hiPSC lines using
state-of-the-art reprogramming technology of well-orchestrated ex-
trinsic stimuli including BMP4 and CHIR followed by WNT inhibition
(via XAV939 or IWR1) and enrichment of cardiomyocytes by supplying
lactate as energy source [7]. The differentiation process can be divided
into four phases, namely cardiovascular induction (day 0–3), cardiac
specification (day 4–7), cardiac cell proliferation (day 8–12) and cardio-
myocyte enrichment (day 13–16) [13]. The results of immunostaining
for cardiomyocyte markers (α-actinin and cTnT) and gap junctional
marker (Cx43) and FACS analysis for SIRPα indicate successful induc-
tion of cardiomyocytes from hiPSC (N90%) after the enrichment phase,
a finding that has well consisted with our previous reports [13]. Tracer
assays demonstrated metabolic substrate shift (fatty acids uptake N
glucose uptake) already beginning in the cardiac cell proliferation
phase. The uptake ratio increased during cardiomyocyte enrichmentFig. 4. In vivo chest coronal images of radionuclide metabolic imaging in a healthy subject
under fasting conditions. Increased cardiac 123I-BMIPP uptake (fatty acids uptakemarker)
(arrow) as compared to 18F-FDG uptake (glucose uptake marker) is identified.process and ultimately reached approximately a 125I-BMIPP (fatty
acid analogue) uptake 10 times higher than 18F-FDG (glucose ana-
logue) uptake. The strongly positive immunostaining for fatty acid
transport protein and fatty acid binding protein nicely corresponded
to the functional properties of hiPSC-CM as assessed by the tracer as-
says performed.
Moreover, we confirmed a time-dependent increase of fatty acid up-
take during cardiac differentiation of hiPSC that is considered as a refer-
ence of isolated Adult hCM. It should be noted that, due to our technical
limitations, the hCM used in this study were isolated from left atrial ap-
pendage. Since our cardiac differentiation protocol would rather result
in ventricular like cells, there might be some differences of metabolic
status between atrial and ventricular hCM.
In general, a mammalian cardiac function is considered to be
maintained by overall oxidative metabolism to generate ATP using
different energy substrates. Switching between one to another de-
pends on environmental factors, and loss of plasticity in substrate
preference is known to play an important role in pathological condi-
tions. Radionuclide imaging approaches for myocardial substrates in-
cluding fatty acids (e.g. 123I-BMIPP) and glucose (e.g. 18F-FDG) have
been demonstrated to contribute to understanding the relationship
between altered myocardial metabolism and abnormal cardiac condi-
tions [17, 18]. Physiologically, under fasting conditions, fatty acid oxida-
tion is the predominant energy source in the human heart (Fig. 4).
Decreased fatty acids metabolism and increased glucose utilization is
observed in pathologic conditions such as ischemic myocardium and
heart failure, while a lack of glucose utilization is found in diabetic car-
diomyopathy. However, still many important issues remain unsolved
including the question whether the alteration of energy substrate rep-
resents a maladaptive process that can be potentially used as a thera-
peutic target or an adaptive process [19]. Present results including the
combination of metabolic tracer uptake studies and recent technology
of hiPSC-CMsuggest potential novel implications ofmetabolic tracer as-
says as a marker for cardiac functional differentiation as well as further
insights into the role of metabolism in cardiac diseases.
In the present in vitro cell uptake assay, we employed the clini-
cally well-established radionuclide imaging tracers 123I-BMIPP and
18F-FDG. 123I-BMIPP is the most frequently used single photon emis-
sion computed tomography (SPECT) tracer for cardiac fatty acid me-
tabolism imaging [20]. After being specifically taken up into cells via
CD36 fatty acid transport proteins, 123I-BMIPP is resistant to beta-
oxidation because of the methyl group at the beta-position. This re-
sults in prolonged cellular tracer retention rendering 123I-BMIPP as
a suitable marker of fatty acid transport. On the other hand, 18F-
FDG is the most widely used positron emission tomography (PET)
tracer for oncological, cardiac and neurological studies. 18F-FDG is
transported into cells via glucose transporters and subsequently
phosphorylated to 18F-FDG-6-phosphate by hexokinase. 18F-FDG-6-
phosphate is not a substrate for further glycolytic pathways and –
as a charged molecule- retained in the cells. Therefore, cellular 18F-
FDG uptake is considered as a reflection of glucose transport and
hexokinase activity [21]. To be noted, we conducted dual tracer up-
take assays to minimize the variation of the experimental setting be-
tween the two tracers. Cells were simultaneously incubated with
both 125I-BMIPP and 18F-FDG. Due to differences in gamma ray en-
ergy spectra (35 keV and 511 keV, respectively) and radioactive
half-lives (59.43 day and 109.8 min, respectively), the respective
amount of each radiotracer contained in the cells could be accurately
measured.
Thus, our study demonstrates that hiPSC-CMmetabolically repre-
sent that of native human cardiomyocytes in vivo and in vitro. As a
result, hiPSC-CM harbour a yet unidentified potential for modelling
of cardiac energy metabolism. Furthermore, tracer uptake assays
might develop into robust and reliable standard validation tests for
cardiac differentiation protocol optimization and preclinical quality
control.
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